Small incisions

Article

Breaking news from the floor of ESCRS

Rayner Intraocular Lenses has been displaying the RaySert, a small incision IOL injector system. With a 1.8 mm diameter external tip, the system is reported to enable surgeons to insert an IOL through a sub 2.5 mm incision, which leads to enhanced patient comfort and recovery.

Adrian Webber, director of sales and marketing at Rayner, explained the appeal of going smaller: “There are big moves among ophthalmic surgeons to implant lenses through smaller incision sizes to fit with their phaco procedures; it reduces the chances of surgically induced astigmatism.” He said that the company is finding that “the smaller the incision the more preferable it is for many surgeons these days.”

“IOL injections through small incisions need not compromise on lens design,” said Ashok Vyas, MD, who has experienced the system first hand.

Designed for use initially with the company’s C-flex range of IOLs, the system assures ease of use with controlled delivery through a single-handed injection system.

“The RaySert is the same overall design as our regular lens injectors,” said Webber. “It is the same loading procedures so that surgeons who are used to our regular lens injector will find with RaySert it is exactly the same except it is now with a smaller incision size.”

“As an innovator in IOL technology, the introduction of the RaySert small incision injector system is a natural progression in delivering physicians with a new level of control and ease in IOL delivery,” says Donald J. Munro, the company’s chairman and managing director.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.